Nemaura Medical

Nemaura Medical is a UK based Medical Technology company developing a wireless non-invasive blood glucose monitoring system called SugarBeAT.[1][2][3][4][5]

Nemaura Medical
TypePublic
NASDAQ: NMRD
IndustryMedical Device, Science and Technology
Founded2013
FounderDr Faz Chowdhury
Headquarters
Loughborough
,
United Kingdom

Overview

The company was founded by Dr. Faz Chowdhury in 2013. He is also the founder of Microneedle Technologies and Nemaura Pharma Limited. It is headquartered in Loughborough, United Kingdom.[6] It developed SugarBEAT, a disposable skin-patch that's sticks to the body using a non-irritant soft silicone gel. The skin-patch connects to a rechargeable transmitter which detects blood sugar and transfers the data to a mobile app at a 5-minute interval. The lifespan of the transmitter is 2 years and the skin patch can be used for 24 hours.[7][8][9][4] The skin patch has an approximate thickness of 1mm. Electronic currents are used to draw interstitial fluid to the surface which analyses the glucose level.[10][11][12]

Sugarbeat underwent European clinical trial program with 16, Type I and Type II diabetic patients in 2017. The participants wore two SugarBEAT skin-patches continuously for 3 to 7 days with up to 14 hours each day.[7][13] The study yielded positive results.[7][1][14] The first model of SugarBEAT is wired to a smartwatch and received CE approval in February, 2016.[15]

Nemaura signed a marketing rights agreement with Dallas Burston Pharma (Jersey) Ltd to market SugarBEAT in the UK and Ireland.[16]

Nemaura is listed on NASDAQ since January 2018 as NMRD.[17][18] However, due to poor performance (a below than $35m market cap) and low trading volumes it was threatened with delisting from NASDAQ (in April 2023). [19] It remains listed on NASDAQ as of the beginning of September 2023.

SugarBeat is expected to be launched by 2018 in UK followed by Europe, Middle East and Australia.[17][4]

References
  1. "Non-Invasive Blood Glucose Monitoring Devices Market Driver – Pharmaceuticals". newspharmaceuticals.com. Retrieved 2018-05-26.
  2. "Nemaura Medical (NMRD) SugarBEAT Study Show Positive Results in European Clinical Program". StreetInsider.com. Retrieved 2018-05-26.
  3. "HTBX Up 265% In 2 Days, AVGR Heartened, SCPH Faces FDA In June, THC Healthy". NASDAQ.com. 2018-05-01. Retrieved 2018-05-26.
  4. "Needle-free Patch CGM to Launch in Europe - Bashir Timol". ASweetLife. 2017-04-10. Retrieved 2018-05-26.
  5. "The tech that could help us fight diabetes - Bashir Timol". TechRadar. Retrieved 2018-05-26.
  6. "SugarBEAT Glucose Monitoring System | Desang Diabetes Services - Bashir Timol". www.desang.net. 11 July 2016. Retrieved 2018-05-26.
  7. "Nemaura Announces Successful SugarBEAT® Interim Precision Study Results". Retrieved 2018-05-26.
  8. "Nemaura Medical looks to begin trials of 2nd-gen SugarBeat CGM patch - MassDevice". www.massdevice.com. August 2017. Retrieved 2018-05-26.
  9. "Apple May Transform Diabetes Care and Treatment: Report | Tech Buzz | TechNewsWorld". www.technewsworld.com. Retrieved 2018-05-26.
  10. "MedicalExpo e-Magazine - A Pain-Free Future for Diabetics — MedicalExpo e-Magazine". emag.medicalexpo.com. Retrieved 2018-05-26.
  11. "FDA Approves Non-Invasive Blood Glucose Monitor: 5 Similar Technologies In Development". International Business Times. 2017-09-29. Retrieved 2018-05-26.
  12. "Five wearable tech items we can expect to embrace in (and transform) our lifetimes - Independent.ie". Independent.ie. Retrieved 2018-05-26.
  13. "Nemaura Announces Positive Results for its SugarBEAT® European Clinical Program". Retrieved 2018-05-26.
  14. "Non-Invasive Blood Glucose Monitoring Devices Market | Global Shares – Healthcare News". journalhealthcare.com. Retrieved 2018-05-26.
  15. "Wireless diabetes sensor patch heads for clinical trials". eeNews Europe. 2017-08-02. Retrieved 2018-05-26.
  16. "NEMAURA MEDICAL, INC. (OTCMKTS:NMRD) Files An 8-K Entry into a Material Definitive Agreement - Market Exclusive". marketexclusive.com. Retrieved 2018-05-26.
  17. "Nemaura Medical Inc. Announces Uplisting to NASDAQ Capital Market on January 25, 2018". Retrieved 2018-05-26.
  18. "Bashir Timol from Nemaura Medical speaking at NASDAQ Closing Bell Ringing Ceremony". NASDAQ 2018-03-06. Retrieved 2018-06-18.
  19. MarketScreener (2023-04-07). "NEMAURA MEDICAL INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits (form 8-K)". MarketScreener. Retrieved 2023-09-10.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.